GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
436
c/survodutide·posted 1 months ago by u/joaquin_ivaturi

genuine question about biopsy that I am slightly embarrassed to ask

Question The Quiet One ×8

dual agonist. That is the whole post, but I will justify it.

Everything else people worry about in c/meta is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort dual agonist out first, and almost nobody does.

I say this having got it wrong for 18 months. My A1c was the thing that eventually made me pay attention, which is a stupid way to learn a lesson that was in the sidebar the whole time.

549 up / 113 down83% upvoted14 commentsid rb97og2 Jun 2026

14 comments

8 in this archive, depth 3

best — the order this archive was captured in

u/renzo_asante24 points·1 months ago

Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.

replysharereportpermalink
u/injection_site_iris-23 points·1 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/slow_logbook_notes301 point·1 months ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/endotoxin_elliemicro6 points·1 months ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/nadia_bakker20 points·1 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
[deleted]7 points·1 months ago

[deleted]

replysharereportpermalink
u/patient_labslip_log4 points·1 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/meera_sandvik16 points·1 months ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →